Answer
Yes, elevations in cholesterol and triglycerides were observed in patients treated with Sylvant (siltuximab), and patients should be managed according to current clinical guidelines for hyperlipidaemia.
Sources for this answer
- SYLVANT 100 mg powder for concentrate for solution for infusionRecordati UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 12Document updated
Sources checked